KOD Kodiak Sciences Inc. Stock Quote

KOD [NASD]

Index	-	P/E	-	EPS (ttm)	-6.01	Insider Own	4.30%	Shs Outstand	52.17M	Perf Week	6.71%
Market Cap	326.59M	Forward P/E	-	EPS next Y	-5.52	Insider Trans	19.57%	Shs Float	47.32M	Perf Month	3.33%
Income	-312.30M	PEG	-	EPS next Q	-1.77	Inst Own	82.00%	Short Float	5.82%	Perf Quarter	-33.87%
Sales	-	P/S	-	EPS this Y	-77.20%	Inst Trans	-6.43%	Short Ratio	1.96	Perf Half Y	-93.39%
Book/sh	11.45	P/B	0.57	EPS next Y	13.80%	ROA	-33.70%	Target Price	18.60	Perf Year	-92.11%
Cash/sh	-	P/C	-	EPS next 5Y	12.40%	ROE	-45.10%	52W Range	4.90 - 131.97	Perf YTD	-92.31%
Dividend	-	P/FCF	-	EPS past 5Y	-60.50%	ROI	-	52W High	-94.98%	Beta	1.87
Dividend %	-	Quick Ratio	8.90	Sales past 5Y	-	Gross Margin	-	52W Low	35.10%	ATR	0.45
Employees	101	Current Ratio	8.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.73	Volatility	6.50% 7.47%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-87.50%	Profit Margin	-	Rel Volume	0.31	Prev Close	6.52
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 10 AMC	Payout	-	Avg Volume	1.40M	Price	6.62
Recom	2.40	SMA20	10.06%	SMA50	-3.42%	SMA200	-89.57%	Volume	352,417	Change	1.53%

Feb-24-22

Downgrade

JP Morgan

Overweight → Neutral

$90 → $21

Feb-11-22

Initiated

Goldman

Buy

$70

Feb-02-22

Upgrade

JP Morgan

Neutral → Overweight

$124 → $90

May-11-21

Upgrade

ROTH Capital

Neutral → Buy

$155 → $149

Mar-12-21

Initiated

Evercore ISI

Outperform

Mar-01-21

Downgrade

Barclays

Equal Weight → Underweight

$52 → $90

Feb-17-21

Downgrade

ROTH Capital

Buy → Neutral

$133 → $155

Jan-25-21

Downgrade

BMO Capital Markets

Outperform → Market Perform

$145 → $148

Dec-17-20

Initiated

Berenberg

Buy

$156

Dec-16-20

Initiated

UBS

Buy

$170

Dec-11-20

Initiated

Citigroup

Neutral

$134

Nov-30-20

Downgrade

JP Morgan

Overweight → Neutral

$74 → $125

Nov-16-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$80 → $125

Nov-13-20

Downgrade

Goldman

Buy → Neutral

$83 → $105

Mar-31-20

Initiated

BMO Capital Markets

Outperform

$74

Mar-03-20

Initiated

Goldman

Buy

$80

Feb-18-20

Downgrade

Barclays

Overweight → Equal Weight

$69

Feb-06-20

Initiated

SunTrust

Buy

Jan-08-20

Initiated

ROTH Capital

Buy

$115

Jan-03-20

Initiated

Jefferies

Buy

$100

May-19-22 08:00AM	Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases PR Newswire +11.83%
May-13-22 01:44PM	Stock rebound uncertain for U.S. biotechs as risks multiply for investors American City Business Journals
May-11-22 12:38PM	Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus Zacks -7.61%
11:14AM	Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth? Simply Wall St.
May-10-22 04:10PM	Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights PR Newswire
May-06-22 08:50AM	Should You Buy Kodiak (KOD) Ahead of Earnings? Zacks
Apr-29-22 05:30AM	Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences PR Newswire
Mar-31-22 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 12.7% Since Last Earnings Report? Zacks
Mar-23-22 06:32PM	2 Net Current Asset Value Stocks to Consider GuruFocus.com
Mar-05-22 11:07AM	2 Dirt Cheap Biotechs to Buy If You're a Contrarian Motley Fool
Mar-04-22 05:10AM	The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals Zacks -10.98%
Mar-03-22 06:21PM	Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More Zacks
10:59AM	Kodiak (KOD) Down More Than 80% in Past 3 Months: Here's Why Zacks
Mar-02-22 10:11AM	Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus Zacks
08:36AM	Why Kodiak Sciences (KOD) Might Surprise This Earnings Season Zacks
Mar-01-22 04:05PM	Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights PR Newswire
Feb-25-22 10:00AM	Here's Why Kodiak Sciences Inc. (KOD) is Poised for a Turnaround After Losing 82.3% in 4 Weeks Zacks
Feb-23-22 06:00PM	Peninsula biotech stock loses 80% after eye drug's late-stage study fails American City Business Journals -80.42%
04:17PM	Why Kodiak Sciences Stock Is Cratering Today Motley Fool
04:03PM	Kodiak Stock Pummeled After Attempt To Improve On Regeneron's Blockbuster Backfired Investor's Business Daily
09:01AM	Palo Alto Is Leading the Nasdaq Higher, but 1 Biotech Is Getting Crushed Wednesday Motley Fool
08:59AM	Kodiak Sciences stock loses more than three-quarters of its value after disappointing drug trial results MarketWatch
06:00AM	Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration PR Newswire
Feb-07-22 05:38PM	Compton Capital Management Inc Buys Union Pacific Corp, GXO Logistics Inc, FedEx Corp, Sells ... GuruFocus.com
12:29PM	Read Why Barclays Analyst Is 'Negatively Biased' On Kodiak Sciences Benzinga
Feb-04-22 08:30PM	Treehouse Foods, Delek US Holdings See Action From Activist Investors Barrons.com
11:55AM	Kodiak (KOD) Completes Enrolling Patients in Retina-Based Studies Zacks
Feb-03-22 05:30AM	Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema PR Newswire
Jan-03-22 04:05PM	Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire +5.51%
Dec-30-21 10:18AM	Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301 Zacks
Dec-23-21 07:38AM	MainStay VP Wellington Mid Cap Portfolio Buys Icon PLC, Digital Turbine Inc, Integra ... GuruFocus.com
Dec-16-21 04:38PM	Aim Growth Series (invesco Growth Series) Buys Workiva Inc, Rapid7 Inc, The Beauty Health Co, ... GuruFocus.com
05:30AM	Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion PR Newswire
Nov-10-21 10:00AM	Kodiak Sciences (KOD) Q3 Loss Widens, Eye Candidate in Focus Zacks -5.14%
09:52AM	Do These Hedge Funds Regret Dumping Kodiak Sciences Inc (KOD)? Insider Monkey
Nov-09-21 04:30PM	Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights PR Newswire
Nov-08-21 04:05PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
Oct-11-21 09:36AM	We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely Simply Wall St.
Sep-10-21 04:47PM	Notable Kodiak Sciences Insider Makes $5.37 Million Buy Benzinga
07:32AM	3 Stocks Insiders Are Buying Benzinga
Sep-08-21 11:30AM	Kodiak Sciences Inc. (KOD) Up 15.7% Since Last Earnings Report: Can It Continue? Zacks
Sep-01-21 05:45AM	Kodiak Sciences Announces New Long-Term Performance Incentive Plan PR Newswire
Aug-31-21 05:02AM	Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference PR Newswire
Aug-20-21 10:14AM	4 Stocks Insiders Are Buying Benzinga
Aug-10-21 10:21AM	Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus Zacks
Aug-09-21 04:01PM	Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights PR Newswire
Jul-29-21 07:00AM	Is This Mid-Cap Biotech Stock a Buy Now? Motley Fool
Jul-27-21 08:05PM	Were Hedge Funds Right About Selling Kodiak Sciences Inc (KOD)? Insider Monkey
Jul-23-21 07:33AM	Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet Benzinga
Jun-09-21 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report? Zacks
May-20-21 07:00PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
May-19-21 09:58AM	Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Kodiak Sciences Inc. (NASDAQ: KOD) Investors GlobeNewswire
May-18-21 02:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Kodiak Sciences Inc. - KOD PR Newswire
May-11-21 11:04AM	Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus Zacks -7.59%
May-10-21 12:30PM	Why Kodiak Sciences Stock Is Tumbling Today Motley Fool -13.00%
05:30AM	Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights PR Newswire
May-06-21 12:19PM	Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat? Zacks -5.04%
May-04-21 12:00PM	What Makes Kodiak Sciences Inc. (KOD) a New Buy Stock Zacks -5.34%
Apr-21-21 06:59PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
Mar-02-21 04:12PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire -7.14%
10:13AM	Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus Zacks
Mar-01-21 05:30AM	Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights PR Newswire
Feb-16-21 06:07AM	Kodiak Sciences' KSI-301 Shows Durable Benefit In Retinal Disease Settings Benzinga -7.29%
Feb-13-21 08:28AM	Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting PR Newswire
Feb-09-21 04:50AM	How One Woman Turned a $40 Million Kuaishou Bet Into $12 Billion Bloomberg
Feb-02-21 07:14AM	Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition PR Newswire +7.01%
Jan-05-21 08:02AM	Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference PR Newswire
Dec-18-20 01:41AM	Is KOD A Good Stock To Buy Now? Insider Monkey
Nov-27-20 03:02PM	Kodiak Sciences, Playa Hotel See Activist Action Barrons.com
Nov-20-20 04:03PM	Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Nov-17-20 09:02PM	Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock PR Newswire
01:16PM	Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study Zacks
Nov-16-20 04:01PM	Kodiak Sciences Announces Proposed Offering of Common Stock PR Newswire
06:53AM	Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration PR Newswire
Nov-12-20 04:12PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
Nov-11-20 11:27PM	Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting PR Newswire
Nov-10-20 11:44AM	Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus Zacks
Nov-09-20 05:30AM	Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights PR Newswire
Oct-26-20 07:53AM	2 Top Healthcare Stocks That Jumped Last Week Motley Fool
Oct-12-20 04:56PM	Hedge Funds Are Getting Bullish On Kodiak Sciences Inc (KOD) Insider Monkey
Oct-05-20 09:02AM	Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion PR Newswire
Sep-02-20 04:08PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
Aug-10-20 05:30AM	Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights PR Newswire
Jul-31-20 06:00AM	How Bill Gates would treat COVID-19 if he were President of the United States Yahoo Finance Video
Jul-16-20 04:38PM	Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress PR Newswire -6.66%
Jul-10-20 04:00PM	Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting PR Newswire
Jul-07-20 08:38AM	Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar PR Newswire
Jul-05-20 03:30PM	Hedge Funds Keep Buying Kodiak Sciences Inc (KOD) Insider Monkey
Jun-12-20 10:20PM	Why Kodiak Sciences (KOD) Stock Might be a Great Pick Zacks
Jun-05-20 12:00PM	Kodiak Sciences Inc. (KOD) Upgraded to Buy: What Does It Mean for the Stock? Zacks -7.40%
May-29-20 01:38PM	Top Small Cap Stocks for June 2020 Investopedia
May-28-20 08:22AM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
May-26-20 11:02AM	Kodiak Sciences' Shares March Higher, Can It Continue? Zacks
May-13-20 07:01AM	Kodiak Sciences Inc. (KOD) Q1 2020 Earnings Call Transcript Motley Fool
May-11-20 04:13PM	Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference PR Newswire
05:30AM	Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights PR Newswire
May-08-20 04:30PM	Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020 PR Newswire
Apr-07-20 11:35AM	Hedge Funds Have Never Been This Bullish On Kodiak Sciences Inc (KOD) Insider Monkey -8.25%
Apr-02-20 04:08PM	Kodiak Sciences Appoints Charles Bancroft to Board of Directors PR Newswire
Mar-24-20 04:23PM	Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naive macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	Director	May 18	Buy	5.97	223,766	1,335,419	15,142,074	May 18 05:30 PM
BAKER BROS. ADVISORS LP	Director	May 17	Buy	5.99	110,824	663,571	14,942,601	May 18 05:30 PM
BAKER BROS. ADVISORS LP	Director	May 16	Buy	5.72	122,100	697,839	14,843,809	May 18 05:30 PM
PERLROTH VICTOR	Chairman and CEO	Feb 25	Sale	8.99	340,000	3,055,988	2,168,038	Feb 28 07:08 PM
PERLROTH VICTOR	Chairman and CEO	Feb 24	Sale	9.20	1,000,000	9,201,700	2,508,038	Feb 28 07:08 PM
BAKER BROS. ADVISORS LP	Director	Feb 17	Buy	54.56	300,000	16,367,881	14,734,965	Feb 17 05:33 PM
BAKER BROS. ADVISORS LP	Director	Feb 16	Buy	54.12	95,165	5,150,173	14,457,794	Feb 17 05:33 PM
BAKER BROS. ADVISORS LP	Director	Feb 15	Buy	54.16	5,800	314,099	14,369,871	Feb 17 05:33 PM
BAKER BROS. ADVISORS LP	Director	Jan 31	Buy	57.22	30,148	1,725,084	14,364,512	Jan 31 05:06 PM
BAKER BROS. ADVISORS LP	Director	Jan 28	Buy	50.42	55,258	2,786,084	14,336,671	Jan 31 05:06 PM
BAKER BROS. ADVISORS LP	Director	Jan 27	Buy	51.76	262,259	13,573,519	14,285,631	Jan 31 05:06 PM
BAKER BROS. ADVISORS LP	Director	Jan 25	Buy	58.90	5,500	323,934	14,027,837	Jan 25 05:40 PM
BAKER BROS. ADVISORS LP	Director	Jan 24	Buy	57.72	362,197	20,905,291	14,022,337	Jan 25 05:40 PM
BAKER BROS. ADVISORS LP	Director	Jan 21	Buy	56.80	133,414	7,577,571	13,660,140	Jan 25 05:40 PM
EHRLICH JASON	See Remarks	Jan 20	Option Exercise	10.29	6,950	71,516	58,491	Jan 24 05:17 PM
EHRLICH JASON	See Remarks	Jan 20	Sale	64.39	6,950	447,494	51,541	Jan 24 05:17 PM
EHRLICH JASON	See Remarks	Dec 20	Option Exercise	10.29	6,950	71,516	58,491	Dec 22 04:35 PM
EHRLICH JASON	See Remarks	Dec 20	Sale	87.60	6,950	608,831	51,541	Dec 22 04:35 PM
EHRLICH JASON	See Remarks	Nov 22	Option Exercise	10.29	6,950	71,516	58,491	Nov 24 04:55 PM
EHRLICH JASON	See Remarks	Nov 22	Sale	99.15	6,950	689,113	51,541	Nov 24 04:55 PM
BORGESON JOHN A.	See Remarks	Nov 10	Sale	115.42	876	101,111	169,443	Nov 12 04:55 PM
EHRLICH JASON	See Remarks	Oct 20	Option Exercise	10.29	6,950	71,516	58,491	Oct 22 04:52 PM
EHRLICH JASON	See Remarks	Oct 20	Sale	111.77	6,950	776,824	51,541	Oct 22 04:52 PM
BAKER BROS. ADVISORS LP	Director	Sep 30	Buy	95.83	86,932	8,330,572	13,526,726	Oct 01 04:58 PM
BAKER BROS. ADVISORS LP	Director	Sep 29	Option Exercise	0.01	149,999	1,500	13,439,808	Oct 01 04:58 PM
EHRLICH JASON	See Remarks	Sep 20	Option Exercise	10.29	6,950	71,516	58,491	Sep 22 05:02 PM
EHRLICH JASON	See Remarks	Sep 20	Sale	99.88	6,950	694,164	51,541	Sep 22 05:02 PM
BAKER BROS. ADVISORS LP	Director	Sep 16	Buy	94.59	1,153	109,064	13,300,993	Sep 17 06:05 PM
BAKER BROS. ADVISORS LP	Director	Sep 15	Buy	94.39	30,685	2,896,216	13,299,840	Sep 17 06:05 PM
BAKER BROS. ADVISORS LP	Director	Sep 07	Buy	93.31	57,501	5,365,227	13,269,155	Sep 09 06:43 PM
EHRLICH JASON	See Remarks	Aug 20	Option Exercise	10.29	5,258	54,105	58,491	Aug 24 04:59 PM
EHRLICH JASON	See Remarks	Aug 20	Sale	91.44	6,950	635,534	51,541	Aug 24 04:59 PM
BAKER BROS. ADVISORS LP	Director	Aug 19	Buy	87.56	83,648	7,323,898	13,211,654	Aug 19 05:12 PM
BAKER BROS. ADVISORS LP	Director	Aug 18	Buy	87.89	22,584	1,984,806	13,128,006	Aug 19 05:12 PM
BAKER BROS. ADVISORS LP	Director	Aug 17	Buy	85.90	8,164	701,254	13,105,422	Aug 19 05:12 PM
BAKER BROS. ADVISORS LP	Director	Aug 13	Buy	88.66	38,264	3,392,579	13,097,258	Aug 13 07:14 PM
BAKER BROS. ADVISORS LP	Director	Aug 12	Buy	87.29	10,986	958,954	13,058,994	Aug 13 07:14 PM
BAKER BROS. ADVISORS LP	Director	Aug 11	Buy	86.11	53,523	4,609,090	13,048,008	Aug 13 07:14 PM
EHRLICH JASON	See Remarks	Jul 20	Sale	86.28	6,950	599,624	53,233	Jul 22 04:37 PM
EHRLICH JASON	See Remarks	Jun 21	Sale	84.90	6,950	590,085	60,183	Jun 23 05:38 PM
EHRLICH JASON	See Remarks	Jun 15	Sale	84.75	1,147	97,208	64,968	Jun 15 07:06 PM
BORGESON JOHN A.	See Remarks	Jun 15	Sale	84.75	1,037	87,886	167,990	Jun 15 07:04 PM
EHRLICH JASON	See Remarks	Jun 15	Sale	80.90	1,454	117,624	67,133	Jun 17 09:26 PM
BORGESON JOHN A.	See Remarks	Jun 15	Sale	80.90	1,290	104,361	170,319	Jun 17 09:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience